版本:
中国

BRIEF-Esperion initiates of phase 2 triplet oral therapy study

March 7 Esperion Therapeutics Inc:

* Esperion announces initiation of phase 2 triplet oral therapy study of bempedoic acid/ezetimibe/atorvastatin

* Esperion Therapeutics Inc - top-line results are expected by Q4 of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐